<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33612017</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1758-1052</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of STD &amp; AIDS</Title>
          <ISOAbbreviation>Int J STD AIDS</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of cabergoline for lactation inhibition in women living with HIV.</ArticleTitle>
        <Pagination>
          <StartPage>654</StartPage>
          <EndPage>661</EndPage>
          <MedlinePgn>654-661</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/0956462420984694</ELocationID>
        <Abstract>
          <AbstractText>We wished to evaluate the efficacy, safety, and acceptability of cabergoline for lactation inhibition in women who live with HIV. In this multicenter prospective observational study, cabergoline was offered as a single oral dose of 1 mg within the first 48 h postpartum. Women were recruited if they delivered a live infant after 35 weeks of gestational age. Participants filled out a questionnaire regarding symptoms of lactation and cabergoline adverse effects on day 2 and day 14 postpartum. On day 14, they also completed a questionnaire about their satisfaction with cabergoline treatment. Prolactin serum level was measured on both visits. Among 68 participants, all but one received cabergoline. The overall effectiveness defined by partial or complete success at day 14 was 98.3% (confidence intervals: 89.5-99.9). At day 14, 67.4% of women who received cabergoline had prolactin serum levels &lt;25 mcg/L (threshold necessary for galactopoiesis). Mild nonspecific adverse effects were experienced by 24 (29.9%) women on day 2 and 24 (41.4%) on day 14, and lasted 48 h or less. Overall, 96% of women were satisfied with cabergoline's ability to prevent postpartum lactation symptoms. In conclusion, cabergoline is an effective, well-accepted, and well-tolerated medication for lactation inhibition in WLWH.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Boucoiran</LastName>
            <ForeName>Isabelle</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0001-9545-6024</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Division of Maternofetal Medicine, 5622Université de Montréal, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Social and Preventive Medicine, 5622École de Santé Publique de Université de Montréal, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Women and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roy</LastName>
            <ForeName>Melissa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Division of Maternofetal Medicine, 5622Université de Montréal, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poliquin</LastName>
            <ForeName>Vanessa</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, 8664University of Manitoba, Winnipeg, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elwood</LastName>
            <ForeName>Chelsea</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, 12358University of British Columbia, Vancouver, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Women's Health Research Institute, Vancouver, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheehan</LastName>
            <ForeName>Nancy L</ForeName>
            <Initials>NL</Initials>
            <AffiliationInfo>
              <Affiliation>Québec Antiretroviral Therapeutic Drug Monitoring Program, 54473McGill University Health Centre, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Physiology, 5622Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thibaudeau</LastName>
            <ForeName>Rosie</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Division of Maternofetal Medicine, 5622Université de Montréal, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferreira</LastName>
            <ForeName>Ema</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Physiology, 5622Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Autmizguine</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Women and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Physiology, 5622Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Division of Infectious Diseases, CHU Sainte-Justine, 5622Université de Montréal, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kakkar</LastName>
            <ForeName>Fatima</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Women and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Division of Infectious Diseases, CHU Sainte-Justine, 5622Université de Montréal, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boucher</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Division of Maternofetal Medicine, 5622Université de Montréal, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Women and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Money</LastName>
            <ForeName>Deborah</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, 12358University of British Columbia, Vancouver, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Women's Health Research Institute, Vancouver, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tulloch</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BC Women's Hospital and Health Centre, Vancouver, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Int J STD AIDS</MedlineTA>
        <NlmUniqueID>9007917</NlmUniqueID>
        <ISSNLinking>0956-4624</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-62-4</RegistryNumber>
          <NameOfSubstance UI="D011388">Prolactin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004873" MajorTopicYN="Y">Ergolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007774" MajorTopicYN="N">Lactation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">(MeSH): lactation</Keyword>
        <Keyword MajorTopicYN="Y">HIV infection</Keyword>
        <Keyword MajorTopicYN="Y">cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">postpartum period</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33612017</ArticleId>
        <ArticleId IdType="doi">10.1177/0956462420984694</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
